Global Gaucher Disease Market 2015-2019
About Gaucher Disease
Gaucher disease is a rare, inherited metabolic disorder caused by the deficiency of the enzyme glucocerebrosidase. This in turn causes the accumulation of certain detrimental lipids in the body, especially the glycolipid glucocerebroside. The lipids are accumulated mainly within the macrophages, blood cells, spleen, liver, and bone marrow. Approximately 34 genetic mutations have been identified that leads to Gaucher disease, out of which there are four most prominent mutations that lead to more than half of the Gaucher disease globally. Some people may have no symptoms of this disease, while some experience severe complications. Some of the clinical manifestations of this disease are hepatosplenomegaly, anemia, thrombocytopenia, and skeletal abnormalities.
TechNavio's analysts forecast the Global Gaucher Disease market to grow at a CAGR of 7.60 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Gaucher Disease market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various drugs used in the therapy of Gaucher disease, which includes:
TechNavio Announces the Publication of its Research Report – Global Gaucher Disease Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global Gaucher Disease Market: Actelion Pharmaceuticals Ltd., Genzyme Corp., Pfizer Inc. and Shire plc
Other Prominent Vendors in the market are: Amicus Therapeutics, Belrose Pharma, Bionaturis, Biosidus, ISU Abxis, JCR Pharmaceuticals, LIXTE Biotechnology, Neuraltus Pharmaceuticals, Protalix BioTherapeutics, Teva Pharmaceuticals, UCB and Utrecht Holdings.
Commenting on the report, an analyst from TechNavio’s team said: “One key trend upcoming in this market is an increase in awareness among regulatory authorities. Regulatory assistance enables drug makers in developing various treatments. The regulatory bodies are also working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area.”
According to the report, the special provisions offered to drugs for orphan diseases such as Zavesca and Cerezyme is the major contributor to the market. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to the vendors for conducting research in this area.
Further, the report states that one of the main challenges that the market faces is the limited patient population. Limited availability of treatment groups prolong the time period during which the vendor can recover R&D expenses of the drug. The restricted patient population also hinders effective evaluation of drugs based on clinical trials.
Actelion Pharmaceuticals, Genzyme, Pfizer, Shire, Amicus Therapeutics, Belrose Pharma, Bionaturis, Biosidus, ISU Abxis , JCR Pharmaceuticals , LIXTE Biotechnology , Neuraltus Pharmaceuticals, Protalix BioTherapeutics, Teva Pharmaceuticals, UCB,Utrecht Holdings, Zywie
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook